Raymond James Financial Services Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $447K | Buy |
15,494
+1,048
| +7% | +$30.2K | ﹤0.01% | 2700 |
|
|
2024
Q2 | $554K | Buy |
14,446
+3,139
| +28% | +$120K | ﹤0.01% | 2454 |
|
|
2024
Q1 | $665K | Buy |
11,307
+1,467
| +15% | +$86.2K | ﹤0.01% | 2311 |
|
|
2023
Q4 | $589K | Sell |
9,840
-2,260
| -19% | -$135K | ﹤0.01% | 2299 |
|
|
2023
Q3 | $460K | Sell |
12,100
-936
| -7% | -$35.6K | ﹤0.01% | 2381 |
|
|
2023
Q2 | $1.19M | Buy |
13,036
+1,624
| +14% | +$148K | ﹤0.01% | 1809 |
|
|
2023
Q1 | $753K | Sell |
11,412
-6
| -0.1% | -$396 | ﹤0.01% | 2088 |
|
|
2022
Q4 | $590K | Sell |
11,418
-262
| -2% | -$13.5K | ﹤0.01% | 2173 |
|
|
2022
Q3 | $798K | Sell |
11,680
-1,667
| -12% | -$114K | ﹤0.01% | 1953 |
|
|
2022
Q2 | $604K | Sell |
13,347
-1,329
| -9% | -$60.1K | ﹤0.01% | 2145 |
|
|
2022
Q1 | $746K | Sell |
14,676
-11,398
| -44% | -$579K | ﹤0.01% | 2138 |
|
|
2021
Q4 | $1.23M | Buy |
26,074
+9,938
| +62% | +$470K | ﹤0.01% | 1842 |
|
|
2021
Q3 | $532K | Buy |
16,136
+2,714
| +20% | +$89.5K | ﹤0.01% | 2327 |
|
|
2021
Q2 | $848K | Sell |
13,422
-12,166
| -48% | -$769K | ﹤0.01% | 2052 |
|
|
2021
Q1 | $1.1M | Buy |
25,588
+2,302
| +10% | +$98.8K | ﹤0.01% | 1791 |
|
|
2020
Q4 | $1.33M | Buy |
23,286
+13,430
| +136% | +$768K | ﹤0.01% | 1531 |
|
|
2020
Q3 | $297K | Buy |
9,856
+1,657
| +20% | +$49.9K | ﹤0.01% | 2286 |
|
|
2020
Q2 | $268K | Buy |
+8,199
| New | +$268K | ﹤0.01% | 2299 |
|